Abstract Title:

The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease.

Abstract Source:

Food Funct. 2019 Sep 5. Epub 2019 Sep 5. PMID: 31486447

Abstract Author(s):

Asma Hoseini, Gholamreza Namazi, Alireza Farrokhian, Željko Reiner, Esmat Aghadavod, Fereshteh Bahmani, Zatollah Asemi

Article Affiliation:

Asma Hoseini


This study was performed to investigate the effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed with 56 patients having T2DM and CHD. The patients were randomly divided into two groups to receive either 500 mg resveratrol per day (n = 28) or placebo (n = 28) for 4 weeks. Resveratrol reduced fasting glucose (β -10.04 mg dL-1; 95% CI, -18.23, -1.86; P = 0.01), insulin (β -1.09 μIU mL-1; 95% CI, -1.93, -0.24; P = 0.01) and insulin resistance (β -0.48; 95% CI, -0.76, -0.21; P = 0.001) and significantly increased insulin sensitivity (β 0.006; 95% CI, 0.001, 0.01; P = 0.02) when compared with the placebo. Resveratrol also significantly increased HDL-cholesterol levels (β 3.38 mg dL-1; 95% CI, 1.72, 5.05; P<0.001) and significantly decreased the total-/HDL-cholesterol ratio (β -0.36; 95% CI, -0.59, -0.13; P = 0.002) when compared with the placebo. Additionally, resveratrol caused a significant increase in total antioxidant capacity (TAC) (β 58.88 mmol L-1; 95% CI, 17.33, 100.44; P = 0.006) and a significant reduction in malondialdehyde (MDA) levels (β -0.21 μmol L-1; 95% CI, -0.41, -0.005; P = 0.04) when compared with the placebo. Resveratrol upregulated PPAR-γ (P = 0.01) and sirtuin 1 (SIRT1) (P = 0.01) in the peripheral blood mononuclear cells (PBMCs) of T2DM patients with CHD. Resveratrol supplementation did not have any effect on inflammatory markers. Four-week supplementation of resveratrol in patients with T2DM and CHD had beneficial effects on glycemic control, HDL-cholesterol levels, the total-/HDL-cholesterol ratio, TAC and MDA levels. Resveratrol also upregulated PPAR-γ and SIRT1 in the PBMCs of T2DM patients with CHD.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.